| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Autolus Therapeutics Q3 2024 Earnings Preview
|
| Nov 11 |
Autolus secures FDA approval for CAR-T cell therapy use in ALL
|
| Nov 11 |
These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA Holdings, Cigna, Humana, Monday.com, and More
|
| Nov 11 |
FDA approves new CAR-T competitor to Gilead’s Tecartus
|
| Nov 11 |
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
|
| Nov 8 |
Autolus wins FDA approval of Aucatzyl for acute lymphoblastic leukemia
|
| Nov 8 |
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
|
| Nov 5 |
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
|
| Nov 3 |
Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%
|
